- Ocugen’s licence to sell Indian COVAXIN vaccine in the US, Canada and Mexico hits stumbling block with phase 2/3 trials in the US on hold by FDA.
- World Health Organisation suspends export of COVAXIN from India pending resolution of deficiencies in GMP.
- US marketing plan for COVAXIN involving pediatric, booster and US Government purchase is challenging.
- Gene therapy and fusion protein approach to eye disease is early stage and challenging.
- Ocugen has interesting programs, but it isn't clear it is resourced to adequately address them.
For further details see:
Where Will Ocugen Stock Be In 5 Years?